“This is the first study to show that [the compound] Cu(ATSM) can increase the abundance of P-gp clearance pumps in an Alzheimer’s model, by 24.1 percent, effectively linking the repair of the blood-brain barrier to a reduction in toxic proteins and improved cognitive function,” Dr. Pyun said.

“By improving the pumps, the brain can finally clear out the trapped waste. Over 56 days, the treatment reduced toxic amyloid-beta by 42 percent and improved spatial learning by nearly 44 percent.”

“Cu(ATSM) is a copper compound with anti-inflammatory and neuroprotective properties that has already progressed to clinical testing for conditions like Parkinson’s and ALS,” Professor Nicolazzo said.

  • qualia@lemmy.world
    link
    fedilink
    English
    arrow-up
    97
    arrow-down
    1
    ·
    5 days ago

    CNS disease drugs (Alzheimer’s, stroke, ALS) translate from mice to humans under 10% of the time. Mouse models like the referenced primary source are poor proxies as they’re engineered for single, clean pathologies (e.g. one mutation), while human neurodegeneration is messier, multifactorial, and not fully replicated even when surface features like amyloid plaques appear.

    • spaghettiwestern@sh.itjust.worksOP
      link
      fedilink
      English
      arrow-up
      36
      arrow-down
      1
      ·
      5 days ago

      Since it’s already in clinical trials for ALS and Parkinson’s, hopefully testing for Alzheimer’s can be done much more quickly than otherwise would be possible.

      • MinnesotaGoddam@lemmy.world
        link
        fedilink
        English
        arrow-up
        22
        arrow-down
        1
        ·
        5 days ago

        Clinical trials for als are a crapshoot. They’ll approve anything for a trial because what can it hurt

        Source: dad was in the radicava trial. Can’t prove it, but he went fast. Probably faster than he would have without. They excluded him from the dataset because he was inconvenient.

      • corsicanguppy@lemmy.ca
        link
        fedilink
        English
        arrow-up
        13
        arrow-down
        3
        ·
        5 days ago

        10% [success]

        So, the same failure rate as […] many […] vaccines.

        Oh, I’m pretty sure vaccines carry a lot more efficacy than 10%.

        • Logi@lemmy.world
          link
          fedilink
          English
          arrow-up
          13
          arrow-down
          1
          ·
          5 days ago

          A vaccine’s efficacy is not the same thing as the success rate of a drug going through trials.

      • AA5B@lemmy.world
        link
        fedilink
        English
        arrow-up
        1
        ·
        4 days ago

        Even going by the description …… if the problem with Alzheimer’s is the damage is done before you see symptoms, fixing them path to damage can only keep it from getting worse.

        Hopefully we’ll eventually see, but I’m in the camp of the only likely cure being prevention. We already know that some lifestyle changes and vaccinations can lower the risk, even if too many of us can’t fix our habits, and our politico-economy prevents us from doing much about environmental risk factors

        The trick is early testing to find the condition before symptoms, then perhaps a treatment like this article would be useful

        • Rolder@reddthat.com
          link
          fedilink
          English
          arrow-up
          2
          ·
          4 days ago

          I wonder what kind of side effects it has. If side effects are minimal or nonexistent, I could see it eventually becoming an OTC thing you just take like a supplement to help reduce your risk in the first place